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The striatum, a major component of the basal ganglia, performs multiple functions
including control of movement, reward, and addiction. Dysfunction and death of striatal
neurons are the main causes for the motor disorders associated with Huntington’s disease
(HD). Brain-derived neurotrophic factor (BDNF), a member of the neurotrophin family,
is among factors that promote survival and proper function of this neuronal population.
Here, we review recent studies showing that BDNF determines the size of the striatum by
supporting survival of the immature striatal neurons at their origin, promotes maturation
of striatal neurons, and facilitates establishment of striatal connections during brain
development. We also examine the role of BDNF in maintaining proper function of the
striatum during adulthood, summarize the mechanisms that lead to a deficiency in BDNF
signaling and subsequently striatal degeneration in HD, and highlight a potential role of
BDNF as a therapeutic target for HD treatment.
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INTRODUCTION
The striatum is the largest component of the basal ganglia.
It is responsible for movement control and is associated with
addictive behaviors. The striatum receives projections from the
entire cortical mantle; processes motor, sensory, and associational
cortical information; and passes it to the output nuclei of the
basal ganglia (Gerfen et al., 1990, 2002; Bolam et al., 2000). Most
striatal functions are mediated by the medium-sized spiny neu-
rons (MSNs), which comprise 95% of the striatum with the rest
being interneurons (Parent and Hazrati, 1995; Kawaguchi, 1997).
MSNs, which use γ-amino butyric acid (GABA) as a transmitter,
are born in the ventricular/subventricular zones (VZ/SVZ) of the
lateral ganglionic eminence (LGE) and migrate to the striatum
during embryogenesis (Hamasaki et al., 2003). They are divided
into two equal size populations based on their projection sites
and protein expression pattern. The MSNs that form the direct
pathway send projections directly to the output nuclei of the basal
ganglia, such as the internal segment of the globus pallidus, the
substantia nigra pars reticulata, and the ventral pallidum. The
other population of the MSNs sits at the origin of the indirect
pathway and projects to the output nuclei of the basal ganglia via
the external segment of the globus pallidus and the subthalamic
nucleus (Bolam et al., 2000). Under normal conditions, activa-
tion of the direct pathway leads to initiation of movement. On
the other hand, activation of the indirect pathway leads to the
opposite physiological effects such as termination of movement
or suppression of unwanted movements (Mink and Thach, 1993).
In addition to their distinct functions, the MSNs of the two
pathways express different sets of neuropeptides and dopamine
receptors: neurons of the direct pathway express substance P (SP)
and the dopamine receptor D1a (DRD1a), while neurons of the
indirect pathway produce enkephalin (Enk) and the dopamine
receptor D2 (DRD2; Kawaguchi, 1997). These distinct expression
patterns in the MSNs of the two pathways are further confirmed in
bacterial artificial chromosome (BAC) transgenic mice expressing
fluorescent proteins under the control of the promoter for either
DRD1a or DRD2 (Day et al., 2006; Shuen et al., 2008).
Recent studies have shown that striatal neurons are depen-
dent on neurotrophins for their development, survival, and
proper function. Increased attention has been given to brain-
derived neurotrophic factor (BDNF) and its function in normal
and pathological conditions. BDNF is a member of the neu-
rotrophin family, which also includes nerve growth factor (NGF),
neurotrophin-3 (NT-3), and neurotrophin-4/5 (NT-4/5). These
secreted proteins exert many biological effects by binding and
activating specific tropomyosin-related kinase (Trk) receptors.
NGF activates TrkA, BDNF and NT4/5 activate TrkB, and NT3
activates TrkC (Reichardt, 2006). Upon binding to BDNF, acti-
vated full-length TrkB triggers multiple intracellular signaling
cascades through protein-protein interactions (Chao, 2003). The
three major pathways, activated by TrkB include: (1) the PLC-
γ pathway that leads to production of diacylglycerol and an
increase in intracellular calcium, and as a result activation of
CAM kinases and PKC; (2) PI-3-kinase pathway that activates
AKT, which mediates anti-apoptotic effects; and (3) MAP/ERK
pathway that activates regulators of protein translation (Segal,
2003). By activating these diverse signaling cascades in neurons,
BDNF can regulate neuronal development and survival, initiation
of neurite outgrowth and path-finding (Bhave et al., 1999; Encinas
et al., 1999; Yamada et al., 1999, 2001). It can also mediate
various synaptic reorganization processes, including formation
and maintenance of dendrites and dendritic spines (McAllister
et al., 1999; Orefice et al., 2013). Deletion of either the TrkB
or Bdnf gene leads to cell atrophy, dendritic degeneration, and
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neuronal loss, as shown in the excitatory neurons of the dorsal
forebrain (Xu et al., 2000a; Gorski et al., 2003). In addition,
BDNF plays an important role in modulating synaptic function
and plasticity such as long-term potentiation (LTP), a cellular
substrate for learning and memory (McAllister et al., 1999; Poo,
2001).
The vital role of neurotrophins in survival of developing
neurons in the peripheral nervous system (PNS) has been well
established (Crowley et al., 1994; Smeyne et al., 1994). In the
PNS, developing neurons at their final location compete for a
limited amount of neurotrophic factors produced by their target
tissues; neurons unable to obtain sufficient amounts of trophic
factors die via programmed cell death (Zweifel et al., 2005).
This mode of survival implies that peripheral target controls
the final size of the innervating neuronal population through
neurotrophic factors. In contrast, the role of neurotrophins in
survival of developing neurons in the central nervous system
(CNS) has not been determined until recently. In this review we
will discuss our reports, demonstrating that in the developing
striatum and LGE, BDNF and NT3 mediate survival of immature
MSNs of the indirect and direct pathways, respectively, at the
place of their origin before they migrate to their final destination
(Baydyuk et al., 2013). Our findings support the idea that a single
neurotrophin might be sufficient and necessary to support sur-
vival of developing neuronal populations in the CNS. Moreover,
we propose a new mode of neurotrophic action in the brain,
suggesting that innervating neurons may control the size of their
target.
It has been shown that neurotrophins participate in the main-
tenance of adult neuronal populations in the brain (Xu et al.,
2000b; Baquet et al., 2004). A modest increase in postnatal
apoptosis was observed in hippocampal and cerebellar granule
cells of TrkB and TrkC knockout mice, however these deletions
do not appear to affect the size of these two neuronal pop-
ulations (Minichiello and Klein, 1996; Alcántara et al., 1997).
The redundancy of neurotrophin-mediated signaling pathways
in brain regions where more than one Trk receptor is present
can provide an explanation for the rather minor effect when one
receptor or its ligands are removed. It is also difficult to assess the
role of neurotrophins, BDNF in particular, in the postnatal CNS
due to lethality of Bdnf -null mice in the first two postnatal weeks.
Generation of several mouse lines with area-specific Bdnf and
TrkB deletions allowed for the detailed examination of their roles
in striatal postnatal growth and maturation. We will review sev-
eral studies that demonstrate important functions of BDNF-TrkB
signaling in promoting somatic growth, dendritic complexity, and
spine density in striatal neurons (Baquet et al., 2004; Rauskolb
et al., 2010; Li et al., 2012).
Deficiency in BDNF signaling has been linked with an increas-
ing number of conditions that cause brain dysfunction, and the
connection between BDNF loss in the striatum and Huntington’s
disease (HD) pathology has been extensively investigated. HD
is caused by the CAG trinucleotide repeat expansion in the
first exon of the gene encoding huntingtin protein (htt; The
Huntington’s Disease Collaborative Research Group, 1993). This
mutation is translated into a polyglutamine (poly Q) stretch
near the amino terminus of htt, which results in a toxic gain
of function (Gusella and MacDonald, 2000). Although mutant
htt is found throughout the HD brain, the striatum is affected
early and more severely during the course of the disease. Striatal
atrophy is due to selective degeneration of the MSNs with neu-
ronal loss of 50–60% (Mann et al., 1993; Vonsattel and DiFiglia,
1998). Interestingly, the MSNs of the indirect pathway, respon-
sible for inhibition of involuntary movement, are preferentially
affected, causing motor symptoms of HD such as uncontrol-
lable sequence of movements called chorea. The exact mecha-
nism behind selective degeneration of striatal neurons remains
to be elucidated, but it has been suggested that reduced trophic
support renders striatal neurons more vulnerable to the toxic
actions of mutant htt. In support of this view, reduced levels
of BDNF protein are detected in the striatum of HD animal
models (Spires et al., 2004; Apostol et al., 2008; Gharami et al.,
2008) and HD patients (Ferrer et al., 2000). The changes in
striatal gene expression profile are similar in HD patients and
mice with BDNF deficiency (Strand et al., 2007). Moreover, lack
of BDNF-mediated signaling alone is sufficient to cause dendritic
abnormalities and neuronal loss in the striatum (Gorski et al.,
2003; Baquet et al., 2004), and progression of HD is accelerated
in Bdnf heterozygous mice (Canals et al., 2004). Importantly, it
has been determined that mutant htt decreases striatal BDNF by
interfering with BDNF synthesis and transport (Zuccato et al.,
2001; Cattaneo, 2003; Gauthier et al., 2004). Furthermore, our
recent study shows that the TrkB receptor is selectively expressed
in striatal MSNs of the indirect pathway, which may explain
why this population of neurons degenerates first in HD patients
(Baydyuk et al., 2011). Taken together, these observations raise
the possibility that reduced levels of striatal BDNF may signif-
icantly contribute to the HD pathogenesis and identify BDNF-
TrkB signaling pathway as a potential therapeutic target for HD
treatment.
BDNF AND TrkB IN THE ADULT AND DEVELOPING
STRIATUM: EXPRESSION PATTERNS
In the adult brain, BDNF protein is found in many regions,
including the cerebral cortex, basal forebrain, striatum, hip-
pocampus, hypothalamus, brainstem, and cerebellum (Conner
et al., 1997). In most brain regions, such as cortex, both Bdnf
mRNA and BDNF protein are present. In contrast, in the striatum
Bdnf mRNA is virtually absent, whereas BDNF protein levels
are high (Figure 1A; Spires et al., 2004; Apostol et al., 2008;
Gharami et al., 2008). BDNF found in the adult striatum is
synthesized and anterogradely transported from the cell bodies
located in the cerebral cortex, substantia nigra pars compacta,
amygdala, and thalamus (Altar et al., 1997; Baquet et al., 2004).
Since the striatum does not produce BDNF but depends on it
for its proper function, abnormalities in anterograde transport
and reduced gene expression from brain regions supplying BDNF
to the striatum might cause neuronal dysfunction and striatal
atrophy.
The expression levels of BDNF fluctuate during development.
In rodents, BDNF is expressed by a number of cells in the hip-
pocampus on embryonic day 15.5 (E15.5), and by E17 it is found
in the piriform cortex, hippocampus, thalamus, hypothalamus
and amygdala, but in only a few cells in the cortex and none in
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FIGURE 1 | BDNF and TrkB expression in adult and developing
striatum. (A) BDNF expression in Bdnf LacZ/+ brain at P21, as revealed by
X-gal staining for β-galactosidase (blue). Scale bars, 500 µm. (B) BDNF
expression in Bdnf LacZ/+ embryos at E16.5, as revealed by
immunohistochemistry to β-galactosidase. The arrow denotes the
substantia nigra. Scale bar, 250 µm. (C) Co-localization of TrkB with DRD2
in the striatum of adult TrkBLacZ/+; D2-EGFP mice in which β-galactosidase
and EGFP serve as indicators for expression of TrkB and DRD2,
respectively. Fluorescent immunohistochemistry with antibodies to
β-galactosidase and EGFP shows that the majority of TrkB-expressing
neurons also express DRD2 in the adult striatum. (D) High co-expression of
TrkB and DRD2 in the young striatum. Nearly all EGFP+ cells expressed
β-galactosidase in the striatum of TrkBLacZ/+; D2-EGFP mice at P10. (E) Low
co-expression of TrkB and DRD1a in the striatum of TrkBLacZ/+;
Drd1a-tdTomato mice at P10. Scale bar, 50 µm. Ctx, cerebral cortex; Hp,
hippocampus; LGE, lateral ganglionic eminence; SNc, substantia nigra pars
compacta; Stm, striatum. This figure is adapted from Baydyuk et al. (2011,
2013).
the striatum (Baydyuk et al., 2013). Cortical expression appears
at postnatal day 4 (P4) and increases with age, reaching the
adult levels by P21 (Baquet et al., 2004). The corticostriatal
connections are also mainly formed during the first postnatal
week (Nisenbaum et al., 1998; Christensen et al., 1999). Thus,
it is unlikely that the cerebral cortex is the main source of
BDNF for immature neurons in the LGE, in contrast to the
adult striatum. Since BDNF is not expressed in the LGE and
the nearby striatum (Figure 1B), but BDNF protein is already
present in this region at E16.5 (Baydyuk et al., 2013), it likely
comes from other brain regions that express BDNF during
embryogenesis and form connections with the LGE and the
developing striatum.
It is equally important to note that since immature neurons
in the LGE have to migrate to the striatum before they send
axons to striatal targets, it is impossible for them to obtain
BDNF from their eventual targets through retrograde transport.
Therefore, the only source of BDNF in the LGE is from axons
of neurons that project to this region. In our recent study, we
show that BDNF is expressed in the substantia nigra at P0 and
E16.5 specifically in neurons positive for tyrosine hydroxylase
(TH; Baydyuk et al., 2013; Figure 1B). It has also been shown
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that nigrostriatal projections are formed by E16.5 (Voorn et al.,
1988; Hu et al., 2004). Furthermore, TH-positive axons are found
in close proximity to dividing LGE progenitor cells as early as E13
(Ohtani et al., 2003). These expression and projection findings
indicate that BDNF from mesencephalic dopaminergic neurons
is the main source of BDNF in the developing striatum and
the LGE.
The TrkB receptor is also widely expressed in the develop-
ing and adult brain. The TrkB mRNA is first detected in the
neuroepithelium and in the neural crest at E9.5 (Klein et al.,
1990). During development the TrkB is present at high lev-
els throughout the brain with regional and cell type specific
fluctuations. In adulthood, TrkB expression is also confined to
specific regions or neuronal subtypes in a complex pattern.
Both TrkB mRNA and protein are present in the developing
and adult striatum (Yan et al., 1997). Interestingly, TrkB is not
equally distributed in all striatal neurons. Instead, it is pref-
erentially expressed by DRD2-expressing MSNs of the indirect
pathway (Figures 1C,D), with 98% of DRD2 MSNs expressing
TrkB at P10 and 43% in adult animal (Baydyuk et al., 2011).
The observed preferential TrkB expression may provide insights
into the selectivity of degeneration associated with HD, where
a greater decrease in the number of DRD2 MSNs is observed
(Reiner et al., 1988). These neurons act to terminate move-
ment associated with the basal ganglia or suppress unwanted
sequences of movements (Bolam et al., 2000). Hence, the loss
of the indirect pathway neurons leads to disinhibition of the
thalamus and increased facilitation of the motor cortex, pro-
ducing hyperkinesias in HD patients (Calabresi et al., 2000).
Direct pathway neurons that express DRD1a are less affected,
and striatal interneurons are mostly spared in patients with HD
(Ferrante et al., 1987a,b). In agreement with these facts, only
18% of DRD1a MSNs express TrkB at P10 (Figure 1E, Baydyuk
et al., 2011). These findings indicate that decreased BDNF-TrkB
signaling may preferentially affect indirect pathway MSNs, which
express most of the TrkB in the striatum, therefore explaining the
selective degeneration of this population and motor phenotype
seen in HD.
ROLE OF BDNF AND NT3 IN SURVIVAL OF DEVELOPING
STRIATAL NEURONS AT THEIR ORIGIN
Striatal projection MSNs originate in the VZ/SVZ of the LGE
between E12 and P2 with a peak around E15, and subsequently
migrate along guiding radial glia into the striatum (Marchand and
Lajoie, 1986; Olsson et al., 1995, 1998). Several factors have been
identified as regulators of striatal neurogenesis and fate determi-
nation. For instance, dopamine coming from the substantia nigra
pars compacta and arriving in the LGE via nigrostriatal pathway
as early as E13 (Voorn et al., 1988; Hu et al., 2004) has been shown
to modulate striatal neurogenesis by influencing the cell cycle of
progenitor cells in the LGE (Ohtani et al., 2003). Marked progress
has also been made in understanding cell fate determination of
striatal neurons. Several transcription factors have been identified
to play a role in differentiation of neuronal precursors into stri-
atal neurons, including Gsh-2, Mash1, and Dlx family members
(Dlx1, Dlx2, Dlx5, and Dlx6) (Anderson et al., 1997; Casarosa
et al., 1999; Corbin et al., 2000; Stenman et al., 2003). However,
until recently it was unclear whether neurotrophins play any role
in neuronal survival, target innervation, dendritic arborization,
and synaptogenesis of developing striatal neurons.
In our recent studies, we demonstrate that neurotrophins are
major players in determining striatal size by promoting survival of
newborn striatal neurons. Selective deletion of TrkB in the striatal
progenitors, using the Dlx5/6-Cre transgene (TrkBDlx), leads to a
50% loss of the MSNs, among which DRD2 population is most
affected with up to 80% loss, while DRD1a MSNs suffer only 22%
loss (Baydyuk et al., 2011). As we discussed above this selective
loss of the MSNs in the indirect pathway is likely due to the
preferential expression of the TrkB receptor by this population
(Figures 1C–E). The magnitude of the observed neuronal loss in
TrkBDlx mutants is similar at P0 and P21, ruling out the possibility
of cell death during postnatal development. We also show that
TrkB signaling does not affect striatal neurogenesis, in contrast
to the cerebral cortex, where its role in promoting proliferation
and differentiation of neuronal precursors is well established
(Bartkowska et al., 2007). Instead, we observe numerous apop-
totic cells in the striatal VZ/SVZ of TrkBDlx mice, indicating
that TrkB signaling is essential for survival of developing striatal
neurons at their origin (Baydyuk et al., 2011).
In agreement with our previous report, global deletion of
BDNF produces similar phenotype, showing selective loss of
DRD2 MSNs and the majority of cell death occurring within
the LGE during embryogenesis (Baydyuk et al., 2013). These
results confirm a crucial role of BDNF-TrkB signaling in survival
of developing MSNs of the indirect pathway and indicate that
developing MSNs need trophic support before they migrate to the
striatum and send out axons.
MSNs of the direct pathway are not affected by deletion of TrkB
or BDNF. Interestingly, signaling via another neurotrophin, NT3,
plays an important role in survival of this neuronal population.
Both NT3 and TrkC proteins are present in the developing stria-
tum, where 86% of DRD1a-expressing neurons are positive for
TrkC. Deletion of either TrkC or NT3 leads to ∼30% loss of total
number of striatal neurons, with 35% reduction in the number
of the MSNs of the direct pathway, whereas MSNs of the indirect
pathway are not significantly affected (Baydyuk et al., 2013). Thus,
the DRD1a-expressing MSNs of the direct pathway are dependent
on the NT3-TrkC signaling for their survival during development.
Similar to BDNF, NT3 is not expressed in the LGE or the striatum.
Both BDNF and NT3 are produced in the midbrain dopaminergic
neurons and anterogradely transported via nigrostriatal pathway
to the LGE and striatum (Figure 2A). Deletion of either BDNF
or NT3 specifically in TH-positive dopaminergic neurons leads
to selective loss of DRD2 or DRD1a MSNs, respectively (Baydyuk
et al., 2013).
Together, these findings establish a novel mode of neu-
rotrophin actions in the CNS. It is distinct from the one that
has been extensively studied in the PNS, where neurons depend
on neurotrophins after they reach their final position and form
connections with their targets, competing for a limiting amount
of target-derived neurotrophins for their survival. These neu-
rotrophin molecules are internalized at axonal terminals and
retrogradely transported to the cell bodies to activate pro-
survival signaling cascades (Zweifel et al., 2005). In this way,
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FIGURE 2 | Role of BDNF in developing, adult, and HD striatum. (A) A
proposed model showing that BDNF and NT3 anterogradely transported
from mesencephalic dopaminergic neurons regulate survival of immature
neurons in the indirect and direct pathways, respectively. Ctx, cerebral
cortex; Stm, striatum; SN, substantia nigra. (B) Cortical BDNF in the adult
striatum mediates dendritic complexity and spine number and morphology.
(C) Mutant htt reduces BDNF-TrkB signaling by inhibiting BDNF gene
transcription, axonal transport of vesicles containing BDNF, retrograde
dendritic transport of TrkB-positive endosomes to the cell body. Panel A is
adapted from Baydyuk et al. (2013).
target tissue determines the final size of the innervating neu-
ronal population. In some cases, PNS neurons also depend on
neurotrophins during neurogenesis before target innervation is
complete (Fariñas et al., 1998; Coppola et al., 2001). Notably,
neurotrophins required for proper formation of these neurons
are highly expressed in the close vicinity of developing neurons
and growing axons (Fariñas et al., 1996, 2001). In contrast, in the
developing striatum survival of immature MSNs at the place of
their origin depends on neurotrophins, anterogradely transported
from the midbrain dopaminergic neurons (Figure 2A). Thus,
we propose that innervating neurons can regulate the size of
their targeting neuronal population in the CNS by regulating
their survival through neurotrophin release at axonal terminals
during embryogenesis and early postnatal development. As a
result, nigrostriatal dopaminergic neurons, a relatively small pop-
ulation, can regulate the size of their large target, the striatum,
by controlling the survival of immature striatal neurons at their
origin.
ROLE OF BDNF IN STRIATAL POSTNATAL GROWTH,
MATURATION, AND MAINTENANCE
To assess the role of BDNF-TrkB signaling in the postnatal devel-
opment and maintenance of the striatum, several conditional
BDNF knockouts have been generated. Since postnatal striatal
BDNF arrives mainly from the cortex, where its expression starts
during first postnatal week, cortical ablation of BDNF provides
a tool to study a role of BDNF-TrkB signaling in the postnatal
striatal growth. Using this approach, Baquet et al. (2004) demon-
strate that the striatum of postnatal forebrain-specific Emx-Bdnf
knockout mice is reduced in volume compared with controls, and
the MSNs have shrunken cell somas, thinner dendrites, and fewer
dendritic spines at P35. Although significant striatal neuronal
loss is not detected at P35 or P120, 35% of striatal neurons
are lost in Emx-Bdnf knockout mice aged beyond 1 year. Thus,
cortical BDNF has a relatively minor role in determining the
number of the MSNs early in life but is required for a long-
term survival and is necessary for normal dendritic morphogen-
esis when BDNF expression rises in the cortex (Baquet et al.,
2004).
Maturity of striatal neurons is determined by several fac-
tors, including expression levels of neuronal markers, complex-
ity of dendritic arbor, and dendritic spine morphology. Studies
using global BDNF deletion in the CNS show that BDNF abla-
tion leads to reduction in striatal volume, dendritic complexity,
and spine density, indicating impaired striatal maturation in
these mutants (Rauskolb et al., 2010; Li et al., 2012). At the
cellular level, DARPP32 (dopamine- and cAMP-regulated phos-
phoprotein, 32 kDa) is a well-established marker of differenti-
ated striatal MSNs, and a key mediator of dopamine signaling
(Svenningsson et al., 2004). Mutant mice with BDNF deletion
show a marked reduction in DARPP32 expression levels and
distribution (Baydyuk et al., 2011; Li et al., 2012). Decrease in
dendritic spine number and size in BDNF mutant mice indi-
cate deficits in formation of corticostriatal synaptic connections,
as dendritic spines are the main targets of excitatory synapses
formed by cortical afferents (Baquet et al., 2004; Rauskolb et al.,
2010; Li et al., 2012). These observations indicate that BDNF is an
important factor for establishing and maintaining corticostriatal
synapses and can influence their strength (Figure 2B).
Morphological, cellular, and functional changes observed in
the striatum of Bdnf and TrkB mutants are often accompanied by
behavioral abnormalities. For instance, mutant mice with either
forebrain-specific deletion of BDNF or TrkB deletion in striatal
progenitors, display hindlimb and forelimb clasping phenotype,
which has also been observed in transgenic lines with motor dys-
function or degeneration, including HD mouse models (Baquet
et al., 2004; Baydyuk et al., 2011). Deletion of the Bdnf gene in
the dopaminergic neurons causes cell deaths of the MSNs of the
indirect pathway and leads to poor performance on the rotarod,
reinforcing the importance of this pathway in motor coordination
(Baydyuk et al., 2013). In agreement with this finding, ablation
of TrkB selectively from these MSNs results in augmented spon-
taneous and drug-induced hyper-locomotion, further indicating
the importance of BDNF-TrkB signaling in the MSNs of the
indirect pathway, which control inhibition of locomotor behavior
(Besusso et al., 2013). Importantly, a disrupted expression of Bdnf
in the HD mouse models advances the onset of motor dysfunc-
tions and produces more severe uncoordinated movements. In all
the studies discussed above, the behavioral pathology correlates
with specific degeneration of the MSNs of the indirect pathway
(Canals et al., 2004).
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DEFICIENCY IN BDNF-TrkB SIGNALING AND HD:
MOLECULAR MECHANISMS AND THERAPEUTIC
IMPLICATIONS
MUTANT HTT ALTERS BDNF GENE EXPRESSION
The pathogenic mechanisms of HD are not fully understood but
are thought to involve the gain of toxic function and/or the loss
of normal activities of htt protein (Borrell-Pagès et al., 2006).
The combination of both mechanisms can lead to a decrease in
striatal BDNF by interfering with BDNF synthesis and transport
(Zuccato et al., 2001; Cattaneo, 2003; Gauthier et al., 2004). Wild-
type htt is known to regulate transcription of multiple genes,
including Bdnf (Zuccato et al., 2001). In rodents and humans, the
Bdnf gene is transcribed from at least eight discrete promoters,
producing different Bdnf mRNA species that encode the same
protein (Aid et al., 2007). The transcripts are generated in dif-
ferent tissues in a stimulus- and development-specific manner
and may have differential subcellular localizations and targets
(Metsis et al., 1993; Timmusk et al., 1993; Pattabiraman et al.,
2005). Zuccato et al. (2001) show that wild-type htt enhances
Bdnf transcription from promoter II, whereas mutant htt sup-
presses Bdnf transcription from promoter II as well as two other
Bdnf promoters in cultured cells and the cerebral cortex of
YAC72 transgenic mice expressing mutant htt with an expanded
tract of 72 glutamines. Wild-type htt promotes transcription
of promoter II by sequestering the repressor element-1 tran-
scription factor/neuron restrictive silencer factor (REST/NRSF)
in the cytoplasm, thereby freeing the nucleus of the inhibitory
complex and allowing transcription to occur (Zuccato et al.,
2003). In contrast, mutant htt is unable to retain REST/NRSF
complex in the cytoplasm, leading to aberrant accumulation
of REST/NRSF in the nucleus and inhibition of Bdnf gene
transcription.
In agreement with these findings, levels of Bdnf mRNA are
reduced in the cerebral cortices of HD patients (Zuccato et al.,
2008). It also has been shown that lower levels of BDNF are
associated with higher numbers of CAG repeats in mutant htt
alleles and correlate with the severity of the disease (Ciammola
et al., 2007). However, this autopsy data should be interpreted
with caution. As mutant htt alters electrophysiological properties
of cortical neurons (Cummings et al., 2009) and neuronal activity
regulates Bdnf gene expression (Aid et al., 2007), we should not
exclude the possibility that the observed reduction in cortical Bdnf
mRNA levels may be secondary to neurodegeneration.
Although most findings are in agreement with the notion
that both mechanisms, suppressed Bdnf gene expression and
deficient BDNF transport, might concomitantly contribute to
reduced levels of BDNF in the striatum of HD patients and
mouse models, several discrepancies still exist between reports
on transcriptional regulation of BDNF by htt. A reduction in
Bdnf transcription would predict reduced levels of BDNF protein
in cerebral cortices of both HD patients and mouse models.
This prediction has been confirmed in one study (Zuccato et al.,
2008) but not in another study (Gauthier et al., 2004), which
uses post-mortem tissues from multiple control subjects and
HD patients. Furthermore, in situ hybridization revealed normal
levels of cortical Bdnf mRNA in aging YAC128 mice that express
the whole human htt gene with 128 CAG repeats (Xie et al.,
2010). Consistent with this observation, levels of cortical BDNF
in YAC128 mice and R6/1 mice, another HD model, were found
to be similar to those in WT mice (Gharami et al., 2008; Xie
et al., 2010). Despite the variations in determining cortical Bdnf
mRNA levels, a significant reduction in striatal BDNF has been
consistently shown in both HD patients and animal models, thus
providing a strong evidence for BDNF as a crucial factor in the
pathogenesis of HD.
MUTANT HTT INHIBITS BDNF AND TrkB TRANSPORT
In addition to controlling Bdnf mRNA production in the cortex,
wild-type htt also regulates BDNF transport along the corticostri-
atal axes (Figure 2C), the main supply line of BDNF in the adult
striatum (Gauthier et al., 2004). Although present in the nucleus,
htt is predominantly found in the cytoplasm, where it interacts
with huntingtin-associated protein-1 (HAP1), a protein involved
in axonal transport via association with p150glued subunit of dyn-
actin, which is an essential part of the microtubule-based motor
complex (Block-Galarza et al., 1997; Engelender et al., 1997; Li
et al., 1998). Gauthier et al. (2004) show that under normal con-
ditions wild-type htt promotes neuronal survival by facilitating
the transport of BDNF-containing vesicles along microtubules.
Consistent with a loss-of-function hypothesis, reduction in wild-
type htt levels leads to attenuated BDNF trafficking. On the other
hand, mutant htt binds tightly to p150glued via HAP1 and prevents
efficient movement of BDNF-containing vesicles. Disruption of
BDNF transport leads to decreased neurotrophic support and
neurotoxicity, which can be rescued by wild-type htt (Gauthier
et al., 2004).
Considering the important role of htt in axonal trafficking
of BDNF-containing vesicles, it has been recently proposed that
htt can also play a role in retrograde transport of the TrkB in
striatal dendrites (Figure 2C). It has been shown that upon BDNF
binding, TrkB-positive endosomes undergo dynein-dependent
retrograde transport along microtubules to the cell body where
TrkB induces survival signals (Watson et al., 1999; Heerssen
et al., 2004; Ha et al., 2008), a mechanism studied primarily in
axons. Recent technical advances that allow to selectively isolate
dendrites from the cell bodies using microfluidic devices (Cohen
et al., 2011), facilitated the investigation of the TrkB vesicular
retrograde transport in control and HD striatal neurons. A study
by Liot et al. shows that upon BDNF stimulation, TrkB binds
to htt and dynein in dendrites of cultured striatal neurons, and
wild-type htt promotes TrkB transport via dynein-dependent
mechanism. In striatal neurons from HD mouse model, mutant
htt alters binding of TrkB-containing vesicles to microtubules
and reduces TrkB retrograde transport in dendrites, leading to
reduced BDNF/TrkB signaling (Liot et al., 2013). These find-
ings demonstrate that in addition to affecting BDNF axonal
corticostriatal transport, mutant htt can also impair retrograde
trafficking of the TrkB-positive endosomes from striatal den-
drites to the cell bodies. This transport alteration may further
impair BDNF-TrkB signaling, which plays a crucial role in the
survival and maintenance of striatal neurons (Baydyuk et al.,
2011).
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BDNF RESCUES HD PHENOTYPE—THERAPEUTIC IMPLICATIONS
The multiple lines of evidence discussed above indicate that
reduction in striatal BDNF signaling plays a pivotal role in the
pathogenesis of HD. As a result, efforts have been made to
examine whether increasing BDNF expression may be a viable
strategy for treating HD. Indeed, increasing striatal BDNF levels
via pharmacological or behavioral stimulation that induces Bdnf
gene expression (Duan et al., 2003; Spires et al., 2004; Peng et al.,
2008; Simmons et al., 2009) or by viral delivery (Cho et al.,
2007), improves disease phenotypes in several HD mouse models.
Early symptoms in HD patients are manifested by cognitive and
memory deficits that precede the characteristic motor dysfunction
(Lawrence et al., 1998; Ho et al., 2003). Similarly, in HD mouse
models, impaired learning and memory, measured as hippocam-
pal LTP, occur prior to motor deficits and neuronal loss (Murphy
et al., 2000; Mazarakis et al., 2005; Van Raamsdonk et al., 2005).
Since BDNF has been shown to modulate LTP, the reduced levels
of BDNF in HD patients and mice can disrupt synaptic changes
important for learning and memory formation. Applying low
concentrations of BDNF to hippocampal slices prepared from
HD mice fully restores LTP (Lynch et al., 2007). Furthermore,
up-regulation of endogenous BDNF levels with an ampakine, a
positive modulator of AMPA-type glutamate receptors, rescues
synaptic plasticity and reduces learning deficits in HD mice
(Simmons et al., 2009).
In addition to promoting survival and inducing synaptic
plasticity, BDNF also regulates adult neurogenesis (Scharfman
et al., 2005; Henry et al., 2007; Bath et al., 2011), which appears
to be altered in HD mouse models and human postmortem
brains (Curtis et al., 2003; Gil et al., 2005; Phillips et al., 2005).
Adenoviral delivery of BDNF to the striatum of R6/2 HD mice
induces striatal neurogenesis (Cho et al., 2007). Majority of the
newly born neurons differentiate to MSNs and become func-
tional, delaying motor impairment and prolonging survival in
R6/2 mice. Similar improvements have been seen in the same HD
mouse model after administration of the antidepressant sertraline
(Peng et al., 2008). By increasing BDNF levels and stimulating
neurogenesis, sertraline treatment results in improved motor
performance, reduced striatal atrophy, and prolonged survival.
To directly evaluate the effect of increased cortical BDNF
supply to the striatum on the progression of HD, our group
and others have examined the consequences of overexpression
of BDNF in the cortex. In our studies, we employ a Bdnf trans-
gene under the control of the promoter for Ca2+/calmodulin-
dependent protein kinase II alpha (Gharami et al., 2008; Xie
et al., 2010). This transgene starts to express BDNF in the cerebral
cortex in the first postnatal week and reaches plateau in the third
postnatal week, as does the endogenous Bdnf gene (Huang et al.,
1999). It also expresses at low levels in the striatum where the
endogenous Bdnf gene is mostly inactive (Gharami et al., 2008;
Xie et al., 2010). We show that the Bdnf transgene is able to greatly
increase BDNF levels in the striata of two HD mouse lines, R6/1
and YAC128, indicating that BDNF overexpressed in the cortex
is efficiently transported to the striatum, despite the presence
of mutant htt. Importantly, BDNF overexpression reverses brain
atrophy, normalizes the expression of several important genes in
the striatum, and ameliorates deficits in motor coordination in
these two HD mouse models (Gharami et al., 2008; Xie et al.,
2010). In addition, overexpression of BDNF in YAC128 mice
prevents loss of striatal neurons, normalizes spine abnormalities
of MSNs, and significantly improves procedural learning (Xie
et al., 2010). In summary, these studies suggest that increasing
striatal BDNF levels may have therapeutic potential for HD.
CONCLUDING REMARKS
We have described the important roles of neurotrophic signal-
ing in the developing, adult, and diseased striatum. We have
examined a novel model of neurotrophic signaling in the devel-
oping striatum, where neurotrophins, anterogradely transported
from the midbrain dopaminergic neurons, provide a vital sup-
port for immature neurons at their origin. However, it remains
unclear whether the mechanisms of action for neurotrophins
derived from the target tissue as seen in the PNS or trans-
ported from the innervating neurons as seen in the striatum,
differ from one another. A comprehensive examination of sig-
naling cascades affected by abolishing BDNF-TrkB signaling in
the developing and adult striatum could provide some insights
into this question. Another major point raised in this review
is that BDNF-mediated neuronal survival is occurring early in
development, at the time when neurons are being generated, and
before mature connections are formed. During postnatal develop-
ment, BDNF arriving via anterograde axonal transport promotes
striatal maturation and influences synaptic connectivity. Thus,
BDNF signaling plays various roles at different stages of neuronal
development.
Numerous studies presented in this review undoubtedly link
BDNF loss in the striatum and HD pathogenesis. Currently,
drugs used to treat HD act on the symptoms and do not slow
or stop the disease progression. Attempting to restore striatal
BDNF levels or activate downstream signaling pathways may have
therapeutic potential in treating HD patients. Indeed, multiple
lines of evidence, discussed above, suggest that restoring cortical
expression, axonal transport, and release of BDNF in the striatum
promotes neuronal survival and improves behavioral phenotypes
in HD animal models. These findings indicate that increasing
BDNF signaling may also overcome functional deficits observed
in HD patients.
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